BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:39:00 PM | Browse: 535 | Download: 495
Publication Name World Journal of Gastroenterology
Manuscript ID 5490
Country of Manuscript Source China
Received
2013-09-10 12:26
Peer-Review Started
2013-09-12 17:09
To Make the First Decision
2013-09-27 16:26
Return for Revision
2013-10-08 12:17
Revised
2013-10-26 10:44
Second Decision
2013-11-13 11:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-11-13 14:50
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-12-11 20:53
Publish the Manuscript Online
2014-01-20 16:41
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Topic Highlights
Article Title Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
Manuscript Source Invited Manuscript
All Author List Tao Lu, Wai-Kay Seto, Ran-Xu Zhu, Ching-Lung Lai and Man-Fung Yuen
Funding Agency and Grant Number
Corresponding author Man-Fung Yuen, MD, PhD, Professor, Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. mfyuen@hkucc.hku.hk
Keywords Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Vaccination; Prevention
Core Tip Hepatocellular carcinoma (HCC), with the majority of cases associated with infection from hepatitis B virus (HBV) or hepatitis C virus (HCV), is the most common primary liver tumor. We introduced risk factors and risk predictive scores associated with HCC development among chronic HBV and HCV infection for its early diagnose and prevention. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could reduce the risk of HBV-related HCC. Pegylated interferon and ribavirin could reduce the risk of HCV-related HCC. Chemopreventive agents in reducing HBV- and HCV-related HCC were also discussed.
Publish Date 2014-01-20 16:41
Citation Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol 2013; 19(47): 8887-8894
Url http://www.wjgnet.com/1007-9327/full/v19/i47/8887.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i47.8887
Full Article (PDF) WJG-19-8887.pdf
Manuscript File 5490-Review.docx
Answering Reviewers 5490-Answering reviewers.pdf
Copyright License Agreement 5490-Copyright assignment.pdf
Peer-review Report 5490-Peer reviews.pdf
Scientific Editor Work List 5490-Scientific editor work list.doc